17-羟孕酮己酸酯使用与产后出血之间的关联
这项回顾性队列研究纳入2010至2014年间使用17α-羟孕酮己酸酯预防早产并分娩的221名女性,按分娩前7天内是否接受给药分组。产后出血总体发生率为7.8%,两组间无显著差异(9.7% vs 7.0%,p=0.478),校正混杂因素后关联仍无统计学意义(aOR 2.9,95%CI 0.5-15.8)。结论认为近期使用17α-羟孕酮己酸酯与产后出血风险无关。
要点
- 分娩前7天内接受17α-羟孕酮己酸酯者占42%(93/221)。
- 产后出血总体发生率为7.8%(18/221)。
- 分娩前7天内给药组产后出血9.7%,未给药组7.0%,差异无统计学意义(p=0.478)。
核心结论
- 近期使用17α-羟孕酮己酸酯预防复发性早产与产后出血风险无关。
研究设计与样本
- 回顾性队列研究,纳入2010至2014年间使用17α-羟孕酮己酸酯预防早产并分娩的女性221例。
- 按分娩前7天内是否接受17α-羟孕酮己酸酯给药进行二分类分组。
- 采用双变量分析比较产后出血频率,并采用多变量分析校正潜在混杂因素。
主要发现
- 221例中93例(42%)在分娩前7天内接受17α-羟孕酮己酸酯,18例(7.8%)发生产后出血。
- 分娩前7天内给药组产后出血9.7%,未给药组7.0%,差异无统计学意义(p=0.478)。
- 校正潜在混杂因素后关联仍无统计学意义(产后出血aOR 2.9,95%CI 0.5-15.8)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate whether receipt of 17α-hydroxyprogesterone caproate within seven days of delivery is associated with increased risk of postpartum hemorrhage. STUDY DESIGN: This was a retrospective cohort study of women who were receiving 17α-hydroxyprogesterone caproate for preterm birth prevention and delivered between 2010 and 2014. Women were dichotomized by whether a dose of 17α-hydroxyprogesterone caproate was administered within seven days of delivery. Demographic and clinical characteristics were examined, including obstetric history and details of 17α-hydroxyprogesterone caproate receipt. Bivariable analyses were used to compare the frequency of postpartum hemorrhage in women stratified by 17α-hydroxyprogesterone caproate receipt within seven days of delivery. Multivariable analysis was used to adjust for potential confounders. RESULTS: Of 221 women who met inclusion criteria, 93 (42%) received 17α-hydroxyprogesterone caproate within seven days of delivery and 18 (7.8%) experienced a postpartum hemorrhage. No differences were observed in the frequency of postpartum hemorrhage between women who did and did not deliver within seven days of 17α-hydroxyprogesterone caproate injection (9.7% vs 7.0%, p=0.478). These findings persisted after adjusting for potential confounders (aOR for PPH 2.9, 95% CI, 0.5-15.8). CONCLUSION: Recent receipt of 17α-hydroxyprogesterone caproate for prevention of recurrent preterm birth is not associated with risk of postpartum hemorrhage.
引用
- Miller ES, Sakowicz A, Roy A, et al. The association between 17-hydroxyprogesterone caproate use and postpartum hemorrhage. Am J Obstet Gynecol MFM. 2019. PMID: 32914089. doi:10.1016/j.ajogmf.2019.04.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。